Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.63 |
| ▸ | MET | P08581 | 1/20 | 0.46 |
| ▸ | GAK | O14976 | 1/20 | 0.43 |
| ▸ | CCNC | P24863 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23999511 | 1.00 | KDR (0.63) | KDRMETGAKCCNCCDK8 | |
| SCHEMBL30210280 | 1.00 | KDR (0.63) | KDRMETGAKCCNCCDK8 | |
| SCHEMBL30180360 | 1.00 | KDR (0.63) | KDRMETGAKCCNCCDK8 | |
| SCHEMBL24006212 | 0.93 | KDR (0.73) | KDRMETKDM4EALDH1A1HPGD | |
| SCHEMBL23999470 | 0.93 | KDR (0.73) | KDRMETKDM4EALDH1A1HPGD | |
| SCHEMBL25826862 | 0.92 | KDR (0.68) | KDRMETCCNCCDK8MAPKAPK2 | |
| SCHEMBL26323743 | 0.88 | KDR (0.63) | KDRMETMAPKAPK2 | |
| SCHEMBL26310703 | 0.86 | KDR (0.50) | KDRMETKDM4EALDH1A1CYP1A2 | |
| SCHEMBL23999513 | 0.85 | MAPKAPK2 (0.52) | KDRGAKMAPKAPK2 | |
| SCHEMBL23999449 | 0.85 | MAPKAPK2 (0.52) | KDRGAKMAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-09-21 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
| WO-2023081854-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2023-05-11 | — | — | WO | disclosed |
| CN-115996939-A | AKT3 modulators | 乔治穆内有限责任公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-115867562-A | AKT3 modulators | 乔治穆内有限责任公司 | 2023-03-28 | — | — | CN | disclosed |
| WO-2021226519-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021226517-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | KDR 3433/4885MET 1498/4885GAK 499/4885 |
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | KDR 3271/4885MET 1336/4885GAK 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.